Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Acinar-Predominant Pattern Correlates With Poorer Prognosis in Invasive Mucinous Adenocarcinoma of the Lung.

Lin G, Li H, Kuang J, Tang K, Guo Y, Han A, Xie C.

Am J Clin Pathol. 2018 Mar 29;149(5):373-378. doi: 10.1093/ajcp/aqx170.

PMID:
29538611
2.

Second predominant subtype predicts outcomes of intermediate-malignant invasive lung adenocarcinoma†.

Ito M, Miyata Y, Yoshiya T, Tsutani Y, Mimura T, Murakami S, Ito H, Nakayama H, Okada M.

Eur J Cardiothorac Surg. 2017 Feb 1;51(2):218-222. doi: 10.1093/ejcts/ezw318.

PMID:
28186287
3.

Prognosis in Resected Invasive Mucinous Adenocarcinomas of the Lung: Related Factors and Comparison with Resected Nonmucinous Adenocarcinomas.

Lee HY, Cha MJ, Lee KS, Lee HY, Kwon OJ, Choi JY, Kim HK, Choi YS, Kim J, Shim YM.

J Thorac Oncol. 2016 Jul;11(7):1064-73. doi: 10.1016/j.jtho.2016.03.011. Epub 2016 Mar 22.

4.

Excellent prognosis of lepidic-predominant lung adenocarcinoma: low incidence of lymphatic vessel invasion as a key factor.

Araki K, Kidokoro Y, Hosoya K, Wakahara M, Matsuoka Y, Takagi Y, Haruki T, Miwa K, Taniguchi Y, Horie S, Nakamura H.

Anticancer Res. 2014 Jun;34(6):3153-6.

PMID:
24922687
5.

Clinical course of stage IV invasive mucinous adenocarcinoma of the lung.

Cha YJ, Kim HR, Lee HJ, Cho BC, Shim HS.

Lung Cancer. 2016 Dec;102:82-88. doi: 10.1016/j.lungcan.2016.11.004. Epub 2016 Nov 6.

PMID:
27987593
6.

Analysis of the clinicopathologic characteristics and prognostic of stage I invasive mucinous adenocarcinoma.

Luo J, Wang R, Han B, Zhang J, Zhao H, Fang W, Luo Q, Yang J, Yang Y, Zhu L, Chen T, Cheng X, Huang Q, Wang Y, Zheng J, Chen H.

J Cancer Res Clin Oncol. 2016 Aug;142(8):1837-45. doi: 10.1007/s00432-016-2201-9. Epub 2016 Jun 24.

PMID:
27342421
7.

Nonpredominant lepidic pattern correlates with better outcome in invasive lung adenocarcinoma.

Mäkinen JM, Laitakari K, Johnson S, Mäkitaro R, Bloigu R, Lappi-Blanco E, Kaarteenaho R.

Lung Cancer. 2015 Dec;90(3):568-74. doi: 10.1016/j.lungcan.2015.10.014. Epub 2015 Oct 17.

PMID:
26506915
8.

Close association of IASLC/ATS/ERS lung adenocarcinoma subtypes with glucose-uptake in positron emission tomography.

Nakamura H, Saji H, Shinmyo T, Tagaya R, Kurimoto N, Koizumi H, Takagi M.

Lung Cancer. 2015 Jan;87(1):28-33. doi: 10.1016/j.lungcan.2014.11.010. Epub 2014 Nov 27.

PMID:
25481488
9.

Prognostic implication of predominant histologic subtypes of lymph node metastases in surgically resected lung adenocarcinoma.

Suda K, Sato K, Shimizu S, Tomizawa K, Takemoto T, Iwasaki T, Sakaguchi M, Mitsudomi T.

Biomed Res Int. 2014;2014:645681. doi: 10.1155/2014/645681. Epub 2014 Oct 12.

11.

Radiologic findings to predict low-grade malignant tumour among clinical T1bN0 lung adenocarcinomas: lessons from histological subtypes.

Mimae T, Miyata Y, Mimura T, Ito H, Nakayama H, Okumura S, Yoshimura M, Okada M.

Jpn J Clin Oncol. 2015 Aug;45(8):767-73. doi: 10.1093/jjco/hyv078. Epub 2015 Jun 7.

PMID:
26056324
12.

Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases.

Yoshizawa A, Motoi N, Riely GJ, Sima CS, Gerald WL, Kris MG, Park BJ, Rusch VW, Travis WD.

Mod Pathol. 2011 May;24(5):653-64. doi: 10.1038/modpathol.2010.232. Epub 2011 Jan 21.

13.

Adenocarcinomas with prominent lepidic spread: retrospective review applying new classification of the American Thoracic Society.

Xu L, Tavora F, Battafarano R, Burke A.

Am J Surg Pathol. 2012 Feb;36(2):273-82. doi: 10.1097/PAS.0b013e31823b3eeb.

PMID:
22198010
14.

Prognostic value of the IASLC/ATS/ERS classification in stage I lung adenocarcinoma patients--based on a hospital study in China.

Song Z, Zhu H, Guo Z, Wu W, Sun W, Zhang Y.

Eur J Surg Oncol. 2013 Nov;39(11):1262-8. doi: 10.1016/j.ejso.2013.08.026. Epub 2013 Sep 11.

PMID:
24063970
16.

Mutational Profile and New IASLC/ATS/ERS Classification Provide Additional Prognostic Information about Lung Adenocarcinoma: A Study of 125 Patients from Brazil.

de Melo AC, Karen de Sá V, Sternberg C, Olivieri ER, Werneck da Cunha I, Fabro AT, Carraro DM, de Barros e Silva MJ, Pimenta Inada HK, de Mello ES, Soares FA, Takagaki T, Ferreira CG, Capelozzi VL.

Oncology. 2015;89(3):175-86. doi: 10.1159/000376552. Epub 2015 Apr 1.

PMID:
25833149
17.

Prognostic significance of adenocarcinoma in situ, minimally invasive adenocarcinoma, and nonmucinous lepidic predominant invasive adenocarcinoma of the lung in patients with stage I disease.

Kadota K, Villena-Vargas J, Yoshizawa A, Motoi N, Sima CS, Riely GJ, Rusch VW, Adusumilli PS, Travis WD.

Am J Surg Pathol. 2014 Apr;38(4):448-60. doi: 10.1097/PAS.0000000000000134.

18.

Correlation of mutation status and survival with predominant histologic subtype according to the new IASLC/ATS/ERS lung adenocarcinoma classification in stage III (N2) patients.

Russell PA, Barnett SA, Walkiewicz M, Wainer Z, Conron M, Wright GM, Gooi J, Knight S, Wynne R, Liew D, John T.

J Thorac Oncol. 2013 Apr;8(4):461-8. doi: 10.1097/JTO.0b013e3182828fb8.

19.

What CT characteristics of lepidic predominant pattern lung adenocarcinomas correlate with invasiveness on pathology?

Aherne EA, Plodkowski AJ, Montecalvo J, Hayan S, Zheng J, Capanu M, Adusumilli PS, Travis WD, Ginsberg MS.

Lung Cancer. 2018 Apr;118:83-89. doi: 10.1016/j.lungcan.2018.01.013. Epub 2018 Feb 3.

20.

Association between high-resolution computed tomography findings and the IASLC/ATS/ERS classification of small lung adenocarcinomas in Japanese patients.

Kudo Y, Matsubayashi J, Saji H, Akata S, Shimada Y, Kato Y, Kakihana M, Kajiwara N, Ohira T, Nagao T, Ikeda N.

Lung Cancer. 2015 Oct;90(1):47-54. doi: 10.1016/j.lungcan.2015.07.007. Epub 2015 Jul 26.

PMID:
26259875

Supplemental Content

Support Center